Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Making Sense of the New Classification Systems for MDS in 2024

Moffitt Cancer Center

R. Komrokji

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Using Transplant in Patients With p53 Mutant MDS or AML

Moffitt Cancer Center

H. Elmariah

The Truth About Current Consensus Statements on Hematopoietic Cell T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Gale

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

Experts Discuss the Latest Data in Myeloid Diseases

Moffitt Cancer Center

A. Kuykendall, R. Komrokji, O. Chan, D. Sallman